Dual-Vector AAV Approval in 61 Days Resets BLA Expectations

Regeneron Pharmaceuticals has secured FDA accelerated approval for Otarmeni (lunsotogene parvec-cwha), a dual adeno-associated virus serotype 1 (AAV1) vector gene therapy for pediatric and adult patients with severe-to-profound sensorineural hearing loss associated with biallelic OTOF gene variants. The 61-day BLA review, executed under the Commissioner's National Priority Voucher (CNPV) pilot program, signals that FDA has operationalized a review infrastructure capable of handling novel dual-vector constructs and biologic-device combination products under compressed timelines, with direct implications for how manufacturers sequence regulatory strategy and CMC submissions.

Otarmeni is the sixth approval under the CNPV pilot and the first gene therapy product cleared through the program, tying the record for fastest BLA approval in modern FDA history. The product is a one-time combination product: dual AAV1 vectors are administered as a single cochlear dose per ear via a syringe, catheter, and infusion pump supplied in a co-approved Administration Kit. Regulatory coordination across multiple FDA offices and centers was required, a complexity FDA Commissioner Marty Makary explicitly cited as evidence the agency can manage accelerated review of submissions involving combination product classification and novel vector architecture. For QA and regulatory affairs teams, the approval confirms that RMAT designation, fast track, orphan drug, and rare pediatric disease designations can be stacked to support CNPV eligibility without sacrificing review rigor.

Clinical and post-market obligations warrant close attention. Efficacy data derive from a single-arm, ongoing, multicenter trial in 24 pediatric patients aged 10 months to 16 years; 20 were evaluable, and 80% demonstrated improved hearing versus the natural history of untreated disease. Accelerated approval conditions require continued verification of hearing improvement durability and clinical measures of speech development and quality of life. No prior disease-modifying treatment existed for OTOF-related deafness before this approval. Common adverse events included middle ear infection, nausea, dizziness, and procedural pain; the therapy is contraindicated where anatomy prevents safe cochlear access, and providers must monitor for surgical complications.

FDA will host a public meeting on June 4, 2026 to solicit stakeholder feedback on CNPV eligibility criteria, voucher selection, sponsor responsibilities, pre-submission requirements, and FDA review procedures. Plant heads and regulatory leads with pipeline assets in rare pediatric or genetic disease indications should treat that meeting as a primary intelligence-gathering opportunity for accelerated pathway planning.